Diagnosis category
Primary brain tumor, metastasis, recurrence, radiation necrosis or uncertain lesion is clarified.
Oncology evaluation directory
Neuro-oncology
Brain Tumor Evaluation
A neuro-oncology review for primary brain tumors or brain metastases, organized around MRI findings, pathology or molecular profile, neurological symptoms, steroid/anti-seizure use and prior surgery, radiation or systemic therapy.
Medical disclaimer: This page is informational and coordination-focused. It does not diagnose, prescribe, promise treatment suitability or replace urgent local medical care.
Clinical file logic
What the specialist needs to understand before any treatment discussion.
Brain tumor coordination requires particular caution because symptoms can change quickly. The first step is to clarify whether the file concerns a primary brain tumor, a brain metastasis from another cancer or an uncertain lesion.
The review includes neurological symptoms, steroid dependence, seizure history, surgical/radiation details and whether urgent local treatment is needed before any international coordination.
MRI details
Recent contrast MRI, lesion number, edema, mass effect and progression compared with prior scans are reviewed.
Pathology/molecular profile
Histology, IDH, MGMT, 1p/19q or other markers are included when available.
Neurological status
Seizures, weakness, speech changes, vision, cognition, headaches and steroid need are documented.
Prior treatment
Surgery, radiation, radiosurgery, temozolomide, immunotherapy or systemic therapy are summarized.
Urgency and travel safety
Risk of rapid deterioration is assessed before any non-local planning.
Evaluation matrix
How the case is reviewed without reducing it to a diagnosis name.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Neurological safety
New deficits or seizures may require immediate local care.
Primary vs metastasis
Treatment logic differs greatly depending on tumor origin.
Imaging chronology
Serial MRI comparison is often more useful than one scan alone.
Steroid dependence
High-dose steroids, edema and infection risk affect suitability and travel.
Documents to prepare
A complete medical file prevents delay and unrealistic expectations.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
Cuba context
How Cuba-related options are framed responsibly.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
Urgency is prioritized
Neurological instability is not managed by travel planning; it requires local medical care.
Specialist routing may be mixed
Neuro-oncology, neurosurgery, radiation oncology and medical oncology may all be relevant.
File clarity protects the patient
The review avoids vague promises when diagnosis or progression is uncertain.
Options discussed in Cuba
Cuba-related options in brain tumours and their limits
Neuro-oncology decisions come from reading molecular pathology and imaging together.
In brain tumours the Cuba-related products mentioned are nimotuzumab (CIMAher) and, in some studies, HeberFERON. Nimotuzumab is an EGFR-directed monoclonal antibody studied alongside radiotherapy, particularly in high-grade glioma, and also in paediatric brainstem tumours. A reported advantage is a milder side-effect profile than comparable agents.
These are planned together with the established approach in glioblastoma — maximal safe resection, radiotherapy and temozolomide-based treatment. Published trials were conducted in defined patient groups, so the expected response is assessed separately according to tumour type and molecular profile. Expectations therefore have to be built separately for each tumour type and molecular profile.
In neuro-oncology the value of a file depends directly on imaging quality. An MRI report alone is not enough; raw images (DICOM) allow assessment of location, oedema, mass effect and previously treated fields. Where pathology exists, IDH mutation, 1p/19q co-deletion and MGMT methylation status are decisive.
Raw imaging required
For MRI and CT, send the image files where possible, not only the report; interpretation is limited without them.
Molecular profile
IDH, 1p/19q and MGMT status directly affect treatment choice and expected course and should be sought in the pathology report.
Neurological urgency
Altered consciousness, uncontrolled seizures, rapidly worsening weakness or signs of raised intracranial pressure require local emergency care first.
When local care comes first
Do not wait for international review if urgent symptoms are present.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
- New seizure, confusion, severe headache, vomiting or loss of consciousness.
- New weakness, speech difficulty, vision changes or balance problems.
- Rapidly increasing steroid need or signs of raised intracranial pressure.
Coordination pathway
From records to written next steps.
- File intakeReports, imaging, summaries and current symptoms are uploaded through the application flow.
- Quality checkThe coordination team checks readability, dates, translation needs and missing items.
- Specialist routingThe case is prepared around a clear medical question and routed to the relevant review pathway.
- Written responseThe patient receives an organized next-step explanation before travel, payment or treatment logistics are considered.
Questions
Before starting the application.
Does this page mean I am suitable for a Cuba-based treatment?
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
Can I send only a short summary?
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
Will the coordinator choose my treatment?
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
What happens if my file is incomplete?
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
Can urgent symptoms be handled through this page?
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
Related evaluation pages
Other oncology files reviewed in the same clinical directory.
Official product information
CIMAher (nimotuzumab) as licensed in Cuba
The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.
- Registration
- Sanitary registration 1745, registered 19 February 2002
- Manufacturer
- Center of Molecular Immunology (CIM), Havana, Cuba
- Approved indications
- Advanced squamous cell carcinoma of the head and neck in combination with radiotherapy or chemoradiotherapy, including nasopharyngeal tumours in stages III/IV with radiotherapy; adult high-grade glioma (glioblastoma multiforme and anaplastic astrocytoma) with radiotherapy; newly diagnosed paediatric high-grade glioma with radiotherapy or chemoradiotherapy; recurrent or refractory paediatric glioma as monotherapy; locally advanced, inoperable oesophageal cancer with chemoradiotherapy.
- Route and schedule
- Intravenous infusion. Adults: 200 mg once weekly for six weeks concurrently with radiotherapy or chemoradiotherapy (induction), then 200 mg every two weeks (maintenance) until clinical progression or intolerance. Paediatric recurrent or refractory glioma as monotherapy: 150 mg/m² weekly for six weeks, then every two weeks.
- Monitoring
- Must be given under the supervision of a physician experienced with intravenous medicines, with close observation during the infusion and for at least one hour afterwards. No premedication is required.
- Contraindications
- History of hypersensitivity to this product, to other products derived from mammalian cells, or to any component of the formulation.
- Reported effects
- Adverse reactions reported in pre- and post-authorisation studies include tremor, chills, nausea, headache, vomiting, anaemia and lowered or raised blood pressure.
Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.
Start with the file
Submit documents before making a travel or treatment decision.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.